Septerna, Inc. (SEPN) - What Are Researchers Thinking About This Stock?

Key Points

• Analysts remain broadly optimistic: Septerna has a “Moderate Buy” consensus from 11 analysts, with an average 12-month price target of $52.44. Recent target increases included Guggenheim at $51 and HC Wainwright at $60.
• Quarterly results exceeded expectations: Septerna reported an adjusted loss of $0.29 per share versus the expected $0.43 loss, while revenue of $26.75 million topped the $19.22 million consensus estimate.
• Insiders have been selling shares: Company insiders sold 31,667 shares worth approximately $1.34 million over the past three months, while several institutional investors established new positions.

Shares of Septerna, Inc. (NASDAQ:SEPN - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eleven analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $52.44.

Several research firms have recently weighed in on SEPN. Guggenheim increased their price objective on shares of Septerna from $45.00 to $51.00 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. HC Wainwright boosted their target price on shares of Septerna from $40.00 to $60.00 and gave the company a "buy" rating in a report on Wednesday, August 12th. Stifel Nicolaus set a $49.00 target price on shares of Septerna in a report on Tuesday, August 11th. Raymond James Financial reaffirmed a "strong-buy" rating and set a $49.00 price target on shares of Septerna in a research report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. increased their price target on Septerna from $38.00 to $48.00 and gave the stock an "overweight" rating in a report on Wednesday, August 19th.

Insider Transactions at Septerna

In related news, COO Elizabeth Bhatt sold 25,000 shares of the company's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $44.00, for a total transaction of $1,100,000.00. Following the sale, the chief operating officer owned 174,209 shares in the company, valued at $7,665,196. This represents a 12.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Daniel D. Long sold 3,334 shares of the firm's stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $34.47, for a total value of $114,922.98. Following the sale, the senior vice president directly owned 96,412 shares of the company's stock, valued at $3,323,321.64. This represents a 3.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 31,667 shares of company stock worth $1,341,010 over the last three months. 5.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Septerna

A number of hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd bought a new position in shares of Septerna during the 4th quarter worth approximately $88,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Septerna during the 2nd quarter worth approximately $211,000. Canada Pension Plan Investment Board acquired a new stake in shares of Septerna during the 2nd quarter worth approximately $298,000. Legal & General Group Plc bought a new stake in shares of Septerna in the 2nd quarter valued at $337,000. Finally, Seven Fleet Capital Management LP bought a new stake in shares of Septerna in the 4th quarter valued at $319,000.

Septerna Stock Performance

NASDAQ:SEPN opened at $38.37 on Friday. Septerna has a fifty-two week low of $17.55 and a fifty-two week high of $51.10. The company has a 50 day simple moving average of $39.44 and a two-hundred day simple moving average of $33.05. The company has a market capitalization of $1.79 billion, a PE ratio of -71.06 and a beta of 2.29.

Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.14. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. The firm had revenue of $26.75 million for the quarter, compared to the consensus estimate of $19.22 million. Research analysts predict that Septerna will post -1.41 EPS for the current year.

Septerna Company Profile

Septerna, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing oral medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in numerous biological processes and are established targets for therapies across a range of diseases.

The company uses its proprietary Native Complex Platform to study GPCRs in their native state and identify small-molecule medicines for targets that have historically been difficult to address.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.